Disease Modifying Activity of Imetelstat in Patients With Heavily Transfused Non-Del(5q) Lower-Risk Myelodysplastic Syndromes Relapsed/Refractory/Ineligible for Erythropoiesis-Stimulating Agents in IMerge Phase
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA（2023）
关键词
Phase 3 trial, MDS, imetelstat, cytogenetic response
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要